The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HLX22 plus trastuzumab and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC): Updated results with additional patients.
 
Jin Li
No Relationships to Disclose
 
Ning Li
No Relationships to Disclose
 
Mudan Yang
No Relationships to Disclose
 
Yanqiao Zhang
No Relationships to Disclose
 
Diansheng Zhong
No Relationships to Disclose
 
Meng Qiu
No Relationships to Disclose
 
Linzhi Lu
No Relationships to Disclose
 
Xiaoming Hou
No Relationships to Disclose
 
Yanru Qin
No Relationships to Disclose
 
Guoping Sun
No Relationships to Disclose
 
Jun Deng
No Relationships to Disclose
 
Zimin Liu
No Relationships to Disclose
 
Bo Liu
No Relationships to Disclose
 
Yuntao Ma
No Relationships to Disclose
 
Jingdong Zhang
No Relationships to Disclose
 
Futang Yang
Employment - Shanghai Henlius Biotech
 
Haoyu Yu
Employment - Shanghai Henlius Biotech
 
Jing Li
Employment - Shanghai Henlius Biotech
 
Qingyu Wang
Employment - Shanghai Henlius Biotech
 
Jun Zhu
Employment - Shanghai Henlius Biotech
 
HLX22-GC Investigators
No Relationships to Disclose